E
EXIthera Pharmaceuticals
EXIthera Pharmaceuticals focuses on the development of stroke prevention and antithrombotic drugs
About EXIthera Pharmaceuticals
eXIthera is a clinical stage biotech company focused on developing small molecule inhibitors of Factor XIa, a key enzyme in the blood coagulation process. The company's primary product, EP 7041, is designed to prevent thrombosis—a condition where blood clots form in blood vessels—without the bleeding risks associated with current treatments. EP 7041 has successfully completed Phase 1 clinical trials, demonstrating safety, tolerability, and an ideal clinical pharmacokinetic profile, along with a validated efficacy marker known as aPTT (activated Partial Thromboplastin Time).
The company operates in the biopharmaceutical market, targeting healthcare providers and patients who require anticoagulation therapy. eXIthera's business model revolves around the research, development, and eventual commercialization of its proprietary small molecule therapeutics. Revenue generation is expected to come from product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
By focusing on a novel approach to anticoagulation that minimizes bleeding risks, eXIthera aims to address a significant unmet need in the medical community, potentially saving lives and reducing healthcare costs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Westborough, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCEquity / VC | Apr 2019 | $6M | $24M | Haisco | — |
| LATE VC✓Equity / VC | Aug 2017 | $0 | — | Schooner Capital | — |
Growth signals
Latest recorded traffic for EXIthera Pharmaceuticals is 370 monthly website visits, down 47.9% over the last three months. EXIthera Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- SCSchooner Capital
Clal Biotechnology Industries
Series B and later1 investor entered at this stage
Haisco
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about EXIthera Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EXIthera Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.